[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100530671":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":19,"responsibleParty":35,"collaborators":7,"id":37,"slug":38,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":41,"acronym":42,"eligibilityCriteria":43,"healthyVolunteers":39,"sex":44,"minAge":45,"maxAge":7,"enrollmentInfo":46,"targetDuration":7,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":58,"overallStatus":22,"whyStopped":7,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"Erasme University Hospital","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DIAGNOSTIC_TEST","FAPI PET\u002FCT","In the department of Nuclear Medicine:\n\n* Installation in a relax chair after weight and height control\n* Placement of a venous line in the upper limb after which an infusion of 500ml of 0.9% NaCl is started.\n* Intravenous injection of 3 MBq\u002Fkg (max 300 MBq) of 18F- FAPI 74 or of 2 MBq\u002Fkg 68Ga-FAPI46",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Benjamin Bondue","CONTACT","+ 32 (2) 555 5758","benjamin.bondue@hubruxelles.be",[20],{"facility":21,"status":22,"city":23,"state":7,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"Medecine","RECRUITING","Brussels","1070","Belgium","BE",{"type":28,"coordinates":29},"Point",[30,31],4.34878,50.85045,{"lat":31,"lon":30},[34],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},{"type":36,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100530671","phase-2-role-of-the-fibroblast-activation-protein-fap-as-biomarker-of-fibrotic-lung-diseases-100530671",false,"NCT06189820","Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases","FAPIPET","Inclusion Criteria:\n\n* Adults patients with a fibrotic lung disease (idiopathic pulmonary fibrosis (IPF) or non-IPF fibrotic ILD) as defined according to the 2022 ATS\u002FERS\u002FJRS\u002FALAT Clinical Practice Guidelines\n\nExclusion Criteria:\n\n* Pregnant or nursing patients\n* Patients with another significant medical condition which, in the investigator's opinion, may interfere with the completion of the study.\n* Patients with an active lung neoplasm or any active neoplasm for blood samples","ALL","18 Years",{"count":47,"type":48},70,"ESTIMATED","INTERVENTIONAL",[51],"PHASE2","To evaluate the effect of an anti-fibrotic treatment initiation on the fibrotic activity as assessed by FAPI PET\u002FCT.",[54,55,56,57],"Pulmonary Fibrosis","Lung Fibrosis","Idiopathic Pulmonary Fibrosis","FAP",[59,57],"Pulmonary fibrosis","2023-12-18",{"date":62,"type":63},"2024-01-05","ACTUAL",{"date":65,"type":63},"2023-03-09",{"date":67,"type":48},"2027-03-09",{"name":5,"class":6},1]